Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN-03
2020-004093-21Phase 2Active
- Sponsor
- ALX Oncology
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of evorpacept and pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by ALX Oncology. Primary endpoint: 12-month overall survival rate. Started Apr 2021; status: active.
02
Drugs
evorpaceptpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2020-004093-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004093-21.